T he Spine Outcomes Research Trial (SPORT) study was designed to provide scientifi c evidence on the effectiveness of spinal surgery versus a variety of nonoperative treatments. The prospective collection of data in SPORT study provides a unique opportunity to correlate symptom duration with outcome. The purpose of this study was to assess the correlation between the duration of symptoms (DOS) before the treatment and the outcome after the treatment of spinal stenosis (SS) and degenerative spondylolisthesis (DS).
The hypothesis of this study was that there exists a specifi c DOS of SS and DS beyond which clinical outcomes would be less favorable than with earlier intervention.
MATERIALS AND METHODS

Study Design
SPORT was conducted at 13 multidisciplinary spine practices in 11 states across the United States. The details of methods have been reported previously.
1,2
Patient Population
All patients had neurogenic claudication or radicular leg pain with associated neurological signs, SS seen on crosssectional imaging, symptoms that had persisted for at least 12 weeks, and physician confirmation that they were a Leg pain (0-6), mean (SE) 1 yr or less surgical candidate. Patients with DS seen on standing lateral radiographs were included in a separate analysis.
Patients with adjacent levels of stenosis were eligible, but those with spondylolysis and isthmic spondylolisthesis were not eligible. Preenrollment nonoperative care was not specified but included physical therapy (68%), epidural injections (55%), chiropractic care (25%), anti-infl ammatory medications (63%), and opioid analgesics (30%).
Enrollment began in March 2000 and ended in February 2005.
Study Interventions
Patients were offered participation in either a randomized or an observational cohort. Participants in the randomized cohort received computer-generated random treatment assignments blocked by center; those in the observational cohort chose their treatment with their physician. The protocol surgery consisted of a standard posterior decompressive laminectomy with or without bilateral single-level fusion (autogenous iliac crest bone-grafting with or without posterior pedicle-screw instrumentation).
The nonoperative protocol was "usual recommended care," which included, at least, active physical therapy, education and counseling with instructions regarding home exercise, and nonsteroidal anti-infl ammatory drugs if the patient could tolerate them.
Because of extensive crossover in the randomized cohort ( i.e. , some patients randomized to nonoperative care received operative care and vice versa) and similar baseline characteristics and outcomes between randomized and observational patients when analyzed by treatment, the two groups were combined in this "as-treated" analysis.
Study Measures
Data used in this study were obtained from patient questionnaires completed at baseline, 6 weeks, 3 months, 6 months, 1 year, 2 years, and 4 years after enrollment or surgery.
Primary outcome measures included the bodily pain (BP), physical function (PF) domains, and mental status domains of the Short-Form Health Survey-36 (SF-36) 3 and the American Academy of Orthopaedic Surgeons' Musculoskeletal Outcomes Data Evaluation and Management System version of the Oswestry Disability Index (ODI). 4 Secondary measures included patient self-reported improvement, work status, and satisfaction with current symptoms. 5 Symptom severity was measured by the Low Back Pain Bothersomeness scale, the Sciatica Bothersomeness Index (SBI), and Leg Pain Bothersomeness Index. 6 , 7 The SF-36 scales and the ODI range from 0 to 100, the SBI from 0 to 24, and the Low Back Pain Bothersomeness scale from 0 to 6. Higher scores indicated more severe symptoms on the ODI, SBI, and Low Back Pain Bothersomeness scale, whereas higher scores indicated less severe symptoms on the SF-36.
Comparison
Differences in baseline characteristics were compared between patients with less than 12 months' or greater than or equal to 12 months' DOS before enrollment. The primary analyses compared changes in the clinical outcome measures from baseline as a function of the timing of surgery within each treatment arm ( i.e. , surgery or nonoperative). The treatment effect of surgery was defined to compare the improvement after surgical intervention. It was defi ned as the change in outcome measure after surgical treatment minus the change in outcome measure after nonoperative treatment. 8 
STATISTICAL ANALYSIS
Statistical modeling was performed with use of SAS software (version 9.1, SAS Institute, Cary, NC), with the procedures PROC MIXED, and S-PLUS software (version 6.2, Insightful, Seattle, WA) was used for all other calculations. Significance was defi ned as a P = 0.05 on the basis of a two-sided hypothesis test.
RESULTS
Of the SS patients, there were 405 patients with symptom duration less than 12 months (SS < 12 months' patients). There were 229 patients in the group with 12 months or greater (SS > 12 months' patients). There was a signifi cant baseline difference ( Table 1 ) in unlisted comorbidities (SS < 12 months' patients, 31%, vs. SS > 12 months' patients, 41%; P = 0.009), patient self-assessed health trend getting worse (57% vs . 64%, respectively, P = 0.003), and treatment preference for surgery at baseline (42% vs . 49%, P = 0.038) favoring DOS fewer than 12 months. There were signifi cant differences in the incidence of a positive straight-leg raise (24% vs . 16%, P = 0.023) and lateral recess stenosis (77% vs . 84%, P = 0.027).
At baseline, there was no instability or spondylolisthesis in the SS patient groups, as described in the methods ( Table 1 ) .
Operative details of the SS patients are described in Table 2 . The majority of patients underwent decompression alone (90% SS < 12 months' patients and 85% SS > 12 months' patients). There were no statistically significant differences in types of fusion or use of instrumentation. There were no statistically signifi cant differences in the number of fusions. A higher percentage of patients in SS more than 12 months' patients had decompression at L4-L5 (90% vs . 97%, P = 0.02). There were no statistically signifi cant differences in operative details or complications such as blood loss, dural tear, or wound complication.
There was an increased percentage of additional surgeries in SS more than 12 months' patients at 2 (6% vs . 10%, P = 0.08), 3 (8% vs . 15%, P = 0.02), and 4 years (9% vs . 19%, P = 0.01). Of the additional surgeries performed, the majority were to address recurrent stenosis or spondylolisthesis (4% vs . 9%). A smaller number were addressed as a new condition (1.2% vs . 3.2%).
Change in outcome measures in surgically treated patients is displayed in Table 3 . Averaged over 4 years, there was statistically signifi cant less improvement in SS more than 12 months' patients versus SS fewer than 12 months' patients in SF-36 BP ( P < 0.001), SF-36 PF ( P < 0.001), and ODI ( P < 0.001). Specifi cally at the 4-year endpoint, the surgically treated patients with DOS less than 12 months (SS < 12 months' patients) demonstrated more improvement than SS fewer than 12 months' patients vs. SS (14) 21 (10) Compensation-any †, n (%) 27 (7) 14 (7) 0.89
Mean body mass index, P = 0.002), and patient satisfaction (70.1% vs . 55%, P = 0.015) ( Table 3 and Figure 1 ). Averaged over 4 years, there was more improvement in the nonsurgically treated SS fewer than 12 months' patients versus SS more than 12 months' patients in SF-36 BP ( P = 0.004), SF-36 PF ( P = 0.02), and ODI ( P = 0.022) ( Table 3 and Figure 1 ). At 4 years, there was more improvement in SS fewer than 12 months' patients versus SS more than 12 months' patients in SF-36 BP (15. Comparing the change in the outcome of the surgically treated patients minus the change in the outcome of the nonsurgically treated patients ( Table 3 and Figure 1 ), there were no statistically signifi cant differences in the treatment effect of surgery between SS fewer than 12 months' patients and SS more than 12 months' patients in primary outcome measures or secondary outcome measures averaged over 4 years or at individual time endpoints. Additional analysis was performed by using a cutoff of 6 months' DOS.
There were no signifi cant differences in outcomes between those patients with DOS greater than or less than 6 months (see Table 1A , Supplemental Digital Content 1, http://links.lww.com/BRS/A573; see Table 2A, Supplemental  Digital  Content  2, http://links.lww.com/BRS/A574; see Table 4 , Supplemental Digital Content 3, http://links.lww.com/BRS/A575; see Figure 2 , Supplemental Digital Content 4, http://links.lww.com/BRS/A576).
In the DS study, there were 397 patients with DOS less than 12 months (DS < 12 months' patients; Table 5, also see Table 5A , Supplemental Digital Content 5, http://links.lww.com/BRS/A577). There were 204 patients with DOS 12 months or more (DS > 12 months' patients).
There were decreased incidences of unlisted medical comorbidities in DS fewer than 12 months' patients versus DS more than 12 months' patients (36% vs . 45%, P = 0.05). There was worse baseline SF-36 Mental Component Summary (49.1 vs . 52.1, P = 0.003), low back pain bothersomeness (4.2 vs . 4.5, P = 0.039) in DS fewer than 12 months' patients versus DS more than 12 months' patients. There was an increased percentage of patients reporting symptoms worsening in DS more than 12 months' patients versus DS fewer than 12 months' patients (66% vs . 57%, P = 0.009). There was an increased percentage of asymmetric depressed refl exes (22% vs . 30%, P = 0.035) and central stenosis (89% vs . 96%, P = 0.005) in DS more than 12 months' patients.
Operative details of the DS patient group are described in Table 6 (also see Table 6A , Supplemental Digital Content 6, http://links.lww.com/BRS/A578). In contrast to the SS patient population, approximately 94% of the patients in both DS groups underwent a spinal-fusion operation and only 6% underwent isolated decompression. There were no statistically signifi cant differences in the method of fusion ( in situ vs. instrumented) between groups. There were no differences in the number of levels decompressed, fusion levels, or complications. There was a trend toward a higher percentage of patients in DS Ͻ 12 months group having no complications (73% vs. 63%, P = 0.051). In contrast to the SS patients, there were no statistically signifi cant differences in the incidence of additional surgeries between treatment groups.
There were no statistically signifi cant differences in primary outcome measures (Table 7, Figure 3 ) between surgically treated patients with degenerative spondylolisthesis with . or , 12 months symptoms. There were no statistically signifi cant differences in secondary outcome measures between surgically treated patients with degenerative spondylolisthesis with . or , 12 months symptoms. There were no statistically signifi cant differences in primary or secondary outcome measures in nonsurgically treated patients between degenerative spondylolisthesis patients with . or , 12 months symptoms. There were no statistically signifi cant differences in the treatment effect in primary or secondary outcome measures between DS fewer than 12 months' patients and DS more than 12 months' patients. Furthermore, there were no statistically signifi cant differences in all outcome measures between DS patients with fewer than or more than 6 months of symptoms (see Table 5A , Supplemental Digital Content 5, http://links.lww.com/BRS/A577; see Table 6A , Supplemental Digital Content 6, http://links.lww.com/BRS/A578; see Table 8 
DISCUSSION
The results of this study showed that patients with SS symptoms for 12 or more months have less improvement in outcome, whether treated surgically or nonsurgically. The duration of DS symptoms for 12 or more months is associated with no difference in outcome of surgical or nonsurgical treatment. The treatment effect of surgery compared with nonoperative treatment is not related to the DOS. The disparity between the SS and DS groups may result from improved outcomes observed in the DS patients with more than 12 months of symptoms (see Figure 4 , Supplemental Digital Content 8, http://links.lww.com/BRS/A580) (DS > 12 months' patients) relative to the SS patients with more than 12 months of symptoms (SS > 12 months' patients). Thus, the surgically treated patients with DOS less than 12 months with SS and DS achieved similar improvement. However, the surgically treated patients with DS for more than 12 months achieved a better outcome than patients with SS. Differences between the SS and DS groups in the nonoperatively treated patients with longer symptom duration were signifi cant in the SF-36 BP domain. Consequently, the treatment effect of surgery was signifi cantly greater in the DS patients in SF-36 PCS, percentage satisfaction with symptoms, and trending toward signifi cance in ODI.
There may be pathophysiological reasons for the differential outcome of DS and SS patients with longer symptom duration. Degenerative spondylolisthesis may result in more episodic symptoms than pure SS. It may be better tolerated for longer symptom duration because of the dynamic nature of the instability. In addition, there is a difference in the distribution of stenosis, with the DS patients having a higher incidence of central stenosis (89% vs . 96%, DS Table 1 ). Central stenosis may be less likely to result in severe irreversible changes. Another possible explanation for the difference between the groups may result from the different treatment types delivered to each group. The majority (96%) of the DS patients underwent fusion, while only a small percentage of the SS patients (average 10%) underwent fusion. It is possible that fusion may reduce late dynamic instability and secondary nerve pain. 9 Alternatively, surgeons may have performed more aggressive decompression consisting of wider laminectomy or more facectomy in patients who underwent fusion where there was no concern about iatrogenic instability. However, there was no statistically signifi cant difference in the percentage of patients who underwent fusion in more than 12 months' or fewer than 12 months' groups. We would expect to fi nd a signifi cant difference if fusions were a major confounder.
At baseline, the SS symptom duration groups were well balanced. There were no clinically signifi cant differences in baseline outcome measures, physical fi ndings, or type of surgical intervention between SS symptom duration groups. The decreased improvement in SS patient outcome was associated with a signifi cantly higher number of revision surgeries in SS more than 12 months' patients.
The association between DOS and patient outcome in SS patients may be explained in part by the pathophysiology of chronic nerve compression. Studies of peripheral nerves have demonstrated that an early consequence of chronic nerve compression is local demyelination and remyelination. 10 Chronic nerve compression has also been shown to cause neurons within the dorsal root ganglion to adopt a regenerative phenotype, thereby undergoing a phenotypic change.
11 These Primary outcomes over time for degenerative spondylolisthesis duration of symptoms 1 year or less and more than 1 year. Surgery P value compares the duration of symptoms 1 year or less to more than 1 year among surgery. Nonoperative P value compares the duration of symptoms 1 year or less to more than 1 year among nonoperative. Interaction P value compares the treatment effect (surgery vs. nonoperative) between the duration of symptoms 1 year or less and more than 1 year. * P values are time weighted, average 4 years (area under curve-P values). Months from baseline Oswestry Surgery P = 0.097 Nonoperative P = 0.036
Interaction P = 0.51 changes may be partly responsible for the alterations in nerve function during the early-period postcompression and may account for the decreased improvement and increased revision rate in SS patients with a DOS more than 12 months. Furthermore, the changes in nerve physiology may be exacerbated by chronic ischemia in the lateral recess. There is a watershed vascular supply between the medullary arterial system of the spinal cord and the radicular arterial system of the nerve roots. 7 The relative hypovascularity of the spinal nerve roots renders them particularly susceptible to local ischemia from extrinsic compression. 7 , 8 We hypothesize that since DS results in a dynamic, not constant, compression, there is less long-term nerve ischemia and demyelination, since the nerves may recover if the spondylolisthesis reduces with posture.
Other studies in the literature did not show a signifi cant effect of preoperative DOS on outcome of treatment of SS or DS 4, 5, [12] [13] [14] [15] [16] or did not examine DOS as a possible predictor of outcome of treatment on SS or DS. 3, [17] [18] [19] [20] [21] [22] Yasar et al report the results of a prospective study of 125 patients with SS with 2-year follow-up. The authors found no correlation between DOS and outcome of treatment, although the incidence of DS was not specifi ed in the population. 4 Jönsson report on a series of 105 patients, approximately 33% DS and 66% SS, who underwent decompressive laminectomy for spinal stenosis. The authors reported a nonsignifi cant trend toward a worse outcome associated with DOS more than 4 years. 23 Among patients with lateral spinal stenosis, the authors also demonstrated that a long preoperative duration of sciatica was associated with poor outcome. 6 Several meta-analyses have failed to report an effect of DOS on the outcome of treatment of SS or DS. 24 Finally, Katz et al reported no effect of longer DOS on the outcome of treatment of SS or DS. The authors reported on a series of 99 patients, with approximately 25% incidence of DS. There was no effect of DOS on medium-term or long-term outcome. 25 There are several limitations to this subgroup analysis. The original SPORT study was designed and powered to compare the outcome of surgically and nonsurgically treated patients. There may be confounding variables that are not equally distributed between the treatment groups in this "as-treated" analysis. For instance, there were signifi cant differences in mental status score and perception of worsening at baseline in the DS patients. Although baseline differences were controlled in the calculation of change in primary outcome measures according to symptom duration, there is the possibility that baseline differences that have not been identifi ed are confounding factors. Another possible difference is in the effect of medical comorbidities on the outcome of treatment. Certainly, patients with signifi cant medical comorbidities may be considered more appropriate for nonsurgical treatment to reduce the risks of surgery. However, in both patient groups, there was no statistically signifi cant difference in the "major" medical comorbidities between groups (SS, Table 1 and DS, Table  1 ). There were differences in unlisted comorbidities, although further information is not available. It is possible that patients with particular comorbidities may have an improved outcome with shorter or longer DOS, since their underlying medical comorbidities may preclude full participation in therapy and nonsurgical treatment. Furthermore, the SPORT study was not specifi cally powered to include analysis of specifi c patient subgroups, and consequently, there is a possibility of type II error. However, SPORT represents the largest study to date on SS and DS patients and is most likely to be powered to answer such detailed questions.
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In summary, patients with SS who have symptom duration more than 12 months have a signifi cantly less improvement in outcome regardless of treatment. Patients who have DS have no difference in outcome associated with DOS. Evidence reveals that surgical intervention is associated with an improved outcome compared with nonsurgical treatment. Prolonged DOS does not affect the effi cacy of surgical intervention.
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➢ Key Points
The study evaluated whether the timing of treatment aff ected outcome in patients with SS and DS. Regardless of the timing of treatment, patients in the surgery group had improved outcomes at all time points relative to the nonoperative treatment group. Patients with SS with greater than 12 months of symptoms had less improvement relative to those with less than 12 months. Patients treated with DS did not have diff erent outcomes according to the DOS.
